The growth of the pharmaceutical industry over the past 20 years has been driven by the R&D investment in discovering new compounds, which can be protected by composition of matter patent claims.
The Paxil Case: Composition of Matter Claims, Polymorphs and 'Follow-on' Patents
The growth of the pharmaceutical industry over the past 20 years has been driven by the R&D investment in discovering new compounds, which can be protected by composition of matter patent claims. There are notable exceptions to this rule, <i>eg,</i> an unexpected and lucrative use for an old compound, like topically-applied minoxidil for hair growth (Rogaine'). But composition of matter patent protection on the active product itself is always a primary plank in protecting a drug franchise, and increases the value of the technology significantly.
By
Ivor R. Elrifi And Nicholas P. Triano, IIIThis premium content is locked for The Intellectual Property Strategist subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
